<DOC>
	<DOCNO>NCT01039961</DOCNO>
	<brief_summary>The purpose study evaluate safety IV infusion GW856553 healthy volunteer .</brief_summary>
	<brief_title>PK Study IV Formulation GW856553</brief_title>
	<detailed_description>The aim study evaluate safety tolerability single intravenous ( IV ) dose GW856553 healthy adult subject investigate relationship PK PD marker within first hour follow administration study drug support progression formulation patient population . Subjects Cohort 1 ( n=4 ) receive single 1mg IV dose ( give 15 minute infusion ) GW856553 . Safety , tolerability PK exposures review , optional cohort ( Cohort 2 ) ( n=4 ) , dose may adjust upward downward base data Cohort 1 . Based result Cohort 1 ( Cohort 2 require ) , Cohort 3 ( n=12 ) dose appropriately receive single IV 15 minute infusion GW856553 . After one week washout , Cohort 3 subject receive single oral dose 15mg GW856553 . Access IV oral PK individual permit calculation absolute bioavailability oral dose . Subjects resident research unit morning prior dose last PK blood sample collect 24 hour dose study drug ( exclude washout period ) .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>AST , ALT , alkaline phosphatase bilirubin â‰¤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Male female 18 75 year age inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhoea Male subject must agree use contraception time first dose study medication seven day follow last dose . Body weight &gt; 50kg ( 110 pound ) body mass index ( BMI ) within range &gt; 19 &lt; 30kg/m2 . Capable give write informed consent , include compliance requirement restriction list consent form . QTcB QTcF &lt; 450 msec . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8g alcohol : halfpint ( ~240 ml ) beer , 1 glass ( 125ml ) wine 1 ( 25ml ) measure spirit . Treatment investigational product within 90 day 5 halflives twice duration biological effect investigational product ( whichever longer ) prior dose study . Exposure four new chemical entity within 12 month prior first dose day . Where participation study would result donation blood blood product excess 500mL within 56 day period . Pregnant female determine positive serum urine hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . Taking prescription nonprescription drug ( include vitamin dietary herbal supplement ) , within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication completion followup visit , unless opinion Investigator Sponsor medication interfere study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>healthy volunteer</keyword>
	<keyword>IV formulation study</keyword>
</DOC>